Overview

Phase II Study of HMPL-453 Tartrate in Patients With Advanced Intrahepatic Cholangiocarcinoma With FGFR2 Fusion

Status:
Not yet recruiting
Trial end date:
2023-06-30
Target enrollment:
Participant gender:
Summary
This is a phase II, single arm, multicenter and open-label study to evaluate the efficacy, safety and pharmacokinetic of HMPL-453 tartrate in patients with advanced intrahepatic cholangiocarcinoma with FGFR2 fusion.
Phase:
Phase 2
Details
Lead Sponsor:
Hutchison Medipharma Limited